GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Cadrenal Therapeutics CVKD · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.37

+39.80%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Cadrenal Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Cadrenal Therapeutics is based in Ponte Vedra, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CVKD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $13.2m. At that date it held total assets of $4.3m and shareholders' equity of $2.7m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 Jan 2023
Employees
3
Head office
822 A1A NORTH, PONTE VEDRA, FL, 32082
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Quang PhamChairman of the Board, Chief Executive Officer, since 2022$1.2m
  • Mr. Matthew SzotChief Financial Officer$868,279
  • Mr. Jeffrey ColeChief Operating Officer$726,301
  • Dr. James FergusonChief Medical Officer
  • Mr. John MurphyIndependent Director$123,303
  • Dr. Glynn WilsonIndependent Director$89,313
  • Dr. Steven ZelenkofskeIndependent Director$108,303

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Clinical-stage biopharmaceutical company with 3 employees focused on novel therapy development.
  • Tecarfarin is an orphan-designated anticoagulant targeting a distinct metabolic pathway.
  • Orphan drug indication for ESRD and AFib patients with no current alternatives.

Weaknesses

  • Only 3 full-time employees limit operational capacity.
  • IPO listing date 20 January 2023 shows recent market entry.
  • Tecarfarin's metabolic pathway involves CYP450 and non-CYP450 processes.

Opportunities

  • Orphan drug designation opens market access for ESRD and AFib patients.
  • Growing demand for anticoagulants in cardiac care segments.
  • Novel therapy design may attract partnerships in Health Care sector.

Threats

  • Limited workforce may hinder clinical trial progress.
  • Competition from established anticoagulants like warfarin.
  • Regulatory hurdles for orphan drug approvals in Health Care.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.